英維克(002837.SZ):擬推2022年股票期權激勵計劃
格隆匯5月17日丨英維克(002837.SZ)公佈2022年股票期權激勵計劃(草案),該激勵計劃擬向激勵對象授予的股票期權數量總計為835萬份,涉及的股票種類為人民幣A股普通股股票,對應的標的股票數量為835萬股,約佔該激勵計劃草案公吿日公司股本總額33,430.5562萬股的2.50%。
該激勵計劃授予激勵對象的股票期權的行權價格為19.27元/股。
該激勵計劃授予的激勵對象總人數為267人,包括公吿該激勵計劃草案時在公司(含下屬子公司、分公司)任職的核心管理人員、核心技術(業務)人員等。
該激勵計劃有效期為自股票期權授予之日起至激勵對象獲授的所有股票期權行權或註銷完畢之日止,最長不超過60個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.